| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Brepocitinib | Systemic lupus erythematosus (SLE) | Phase 2b | Trial Discontinued | Oral | Immunology |
| Roivant Sciences Ltd. | Mosliciguat - (PHocus) | Pulmonary hypertension associated with interstitial lung disease (PH-ILD) | Phase 2 | Enrollment Conclusion | Oral | Respiratory |
| Roivant Sciences Ltd. | Cerdulatinib (DMVT-502) | Vitiligo | Phase 2 | Trial Discontinued | Oral | N/A |
| Roivant Sciences Ltd. | Namilumab - (RESOLVE-Lung) | Sarcoidosis | Phase 2 | Trial Discontinued | Intravenous infusion | Respiratory |
| Roivant Sciences Ltd. | Batoclimab | Warm Autoimmune Hemolytic Anemia | Phase 2 | Trial Discontinued | Intravenous | Hematology |
| Royalty Pharma plc | Zidesamtinib (NVL-520) - (ARROS-1) | ROS1 Non-small cell lung cancer (NSCLC) | PDUFA | Data Released | Oral | Oncology |
| Royalty Pharma plc | Aficamten (CK-274) - (MAPLE-HCM) | Obstructive hypertrophic cardiomyopathy (HCM) | Phase 3 | Data Released | Oral | Cardiology |
| SAB Biotherapeutics Inc. | SAB-185 | COVID-19 | Phase 3 | Trial Completed | Intravenous | COVID-19 |